GLORY

• Research type

  Research Study

• Full title

  A Global, Prospective, Non-Interventional Study to Collect Patient and Physician Satisfaction in Routine Clinical Practice During Long Term Treatment of Glabellar Lines and/or Lateral Canthal Lines with Relfydess®

• IRAS ID

  357713

• Contact name

  Priyanka Chada

• Sponsor organisation

  Galderma

• Duration of Study in the UK

  2 years, 3 months, 12 days

• Research summary

  This is a global, prospective, longitudinal, non-interventional, multi-center study to collect patient and physician satisfaction, and treatment experience with Relfydess in routine clinical practice.
  Formally, the present project is a non-interventional study (NIS); owing to this fact, the visit structure is not defined by the study protocol/ observational plan but is determined by routine clinical practice.
  The following observational visits are planned*:
  • Treatment Cycle 1 visits: Screening/Baseline, Treatment 1 (GL and LCL); Follow up (2-3 weeks from first treatment visit)
  • Treatment Cycle 2 visits: Treatment 2 (GL and/or LCL) at least 12 weeks from first treatment visit; Follow up (2-3 weeks from second treatment visit)
  • Treatment Cycle 3 visits: Treatment 3 (GL and/or LCL) at least 12 weeks from second treatment visit; Follow up (2-3 weeks from third treatment visit)
  • Final Follow up; 3-6 months after last treatment.
  Adult male and female patients eligible for Relfydess treatment for moderate to
  severe GL and LCL, are planned to be included in the study. Study participation for
  each patient is anticipated to be up to 21 months, based on the number of treatment
  cycles completed during the first 15 months of the study.

• REC name

  Wales REC 4

• REC reference

  25/WA/0275

• Date of REC Opinion

  17 Sep 2025

• REC opinion

  Favourable Opinion